SRT 1720

• UNSPSC Description:

  SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.

• Target Antigen:

  Autophagy; Sirtuin

• Type:

  Reference compound

• Related Pathways:

  Autophagy;Cell Cycle/DNA Damage;Epigenetics

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/srt-1720.html

• Purity:

  99.90

• Solubility:

  DMSO : 31.82 mg/mL (ultrasonic;warming;adjust pH to 2 with 1 M HCL;heat to 60°C)

• Smiles:

  O=C(NC1=C(C=CC=C1)C2=CN3C(SC=C3CN4CCNCC4)=N2)C5=NC6=C(N=C5)C=CC=C6

• Molecular Weight:

  469.56

• References & Citations:

  [1]Milne JC et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29;450(7170):712-6|[2]Baur JA, et al. Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov. 2012 Jun 1;11(6):443-61|[3]Yao H, et al. SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice. J Clin Invest. 2012 Jun 1;122(6):2032-45.|[4]Yu L, et al. Protective effects of SRT1720 via the HNF1α/FXR signalling pathway and anti-inflammatory mechanisms in mice with estrogen-induced cholestatic liver injury. Toxicol Lett. 2016 Dec 15;264:1-11.Aging Cell. 2021 Oct 3;e13491.|Am J Chin Med. 2020;48(7):1693-1713.|Authorea. September 07, 2022.|Biochem Biophys Res Commun. 2022.|Biochimie. 2020 Mar;170:10-20.|Biomed Pharmacother. 2023 Jun 12;164:114987.|Biomed Pharmacother. 2023 May 24;164:114925.|Biomedicines. 2023 Jun 1, 11(6), 1615.|Brain Res Bull. 2024 Oct 11:111101.|Cell Death Dis. 2024 Jun 28;15(6):462.|Cell Signal. 2024 Oct 18:111478.|Environ Pollut. 2021, 116840.|Environ Toxicol Pharmacol. 2024 Feb 15:106:104393.|Exp Eye Res. 2023 Apr 2;109464.|FASEB J. 2024 Jun;38(11):e23681.|Heliyon. 2024 May 23.|J Neuroinflammation. 2021 Dec 10;18(1):287.|J Transl Med. 2023 Jul 20;21(1):486.|J Transl Med. 2024 Feb 15;22(1):155.|Mol Biol Rep. 2020 Mar;47(3):2149-2159.|Mol Med Rep. 2021 Jan;23(1):20.|Mol Med Rep. 2019 Feb;19(2):1040-1048. |Nat Commun. 2024 Aug 14;15(1):7000.|Oxid Med Cell Longev. 2021 Feb 28.|Phytomedicine. 26 June 2022, 154289.|Res Sq. 2024 May 31.|Sci Total Environ. 2023 Oct 6:167636.|Toxicol Lett. 2016 Dec 15;264:1-11.|Toxicol Res (Camb). 22 July 2022.|Toxicol Sci. 2019 Aug 1;170(2):476-488.|Toxicology. 2024 Jun 10:153861.|Acta Pharm Sin B. 27 August 2022.|Cell Mol Immunol. 2022 Jun 23;1-11.|Food Funct. 2021 Apr 24.|Hypertension. 2016 Nov;68(5):1191-1199. |Int J Mol Med. 2019 Feb;43(2):839-849.|Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2961-2966. |Research Square Preprint. 2024 Mar 19.|Research Square Print. 2022 Jul.|Sci Adv. 2022 Apr 8;8(14):eabj7110.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  925434-55-5